Affimed GmbH articles

A Phase 1 Study Investigating the Combination of AFM13 and the Monoclonal Anti-PD-1 Antibody Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymphoma after Brentuximab Vedotin Failure: Updated Safety and Efficacy Data

AFM13 is a first-in-class tetravalent, bispecific NK cell engager that binds to CD30 on tumor cells and CD16A on NK cells. By engaging CD16-positive NK cells, AFM13 leads to NK cell-mediated killing of tumor cells.

Jul. 1, 2022

Nancy L Bartlett;Robert W Chen;Eva Domingo-Domenech;Andres Forero-Torres;Ramon Garcia-Sanz;Philippe Armand;Sumana Devata;Antonia Rodriguez Izquierdo;Izidore S Lossos;Craig B Reeder;Taimur Sher